30 closest matches · ranked by relevance
Polypharmacy
Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants
Epilepsies, Partial
Primary: Number of Participants With Treatment-Related Adverse Events Unexpected From Japanese Package Insert — 27 participants
Rheumatoid Arthritis
Primary: Total Number of Patients With Adverse Events — 27.8 Percentage of Patients
Panic Disorder · Depression
Primary: Number of Participants of Treatment Related Adverse Events (TRAEs) — 263 participants
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001
HIV-1 Infection
Primary: Number of Participants Who Reported Unlisted Adverse Drug Reaction. — 0 participants
Smoking Cessation
Primary: Risk Factors for the Frequency of Treatment Related Adverse Events - Gender. — 377; 336 participants — p=<0.001
Healthy Volunteers
Primary: Maximum Level of Sedation for Lorazepam 1 mg IM + ADASUVE 10 mg — 12.3 units on a scale
Breast Neoplasms
Primary: Number of Participants With Factors Considered to Affect the Safety and/or Efficacy of Exemestane — 126; 324; 372; 68 participants
Human Immunodeficiency Virus Infection
Primary: Percentage of Participants With Adverse Drug Reactions — 37.73 percentage of participants
Alcohol Use Disorder
Primary: Reinforcing Effects (Pre-Alcohol Dose Consumption) — 0.005; .01; 0.007; 0.005 Units on a Theoretical Scale
Schizophrenia
Primary: Assessment of Negative Symptoms and Neuroleptic Induced Deficit Syndromes by Objective Rating Scales — -1.30; -0.28; -0.66; -0.70 units on a scale
Major Surgery
Primary: Clinically Meaningful Respiratory Compromise Events — 45 Events
Methamphetamine Use Disorder
Primary: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance. — 0; 0; 3.33; 7.25 Trials Completed
Non-tuberculous Mycobacterial Diseases · Tuberculosis · Inhibition of Disseminated Mycobacterium Avium Complex Disease Associated With HIV Infections
Primary: Number of Patients With Adverse Drug Reactions in This Surveillance — 16; 7 Participants
Overactive Bladder
Primary: Confirmation of the Incidence of All Treatment Related Adverse Events (TRAEs). — 984 participants
Cognitive Deficits
Primary: Change From Baseline in COWA Unique Word Count — -0.407725385; -0.425898667; -0.412534118; -0.108298333 Word Count
Tuberculosis · Non-tuberculous Mycobacterial Diseases (Including MAC Disease)
Primary: Number of Participants With Treatment-Related Adverse Events — 387; 113 Participants
Adverse Drug Interactions
Primary: Midazolam Clearance (Pharmacokinetic Measure of Cytochrome P450 3A4 Activity) — 604; 552; 541; 156 ng*min/ml
Pulmonary Hypertension
Primary: Number of Participants With Treatment-Related Adverse Events — 448; 101 Participants
Non-small Cell Lung Cancer
Primary: Number of Participants With Adverse Drug Reactions — 1858; 518 Participants
Drug Interactions
Primary: Difference in Clinically Significant Visual Analogue Scale for Pain and Nausea Change Between CYP2D6 Users and Non-users — 7.4; 10.9; -14.0 millimeters
Staphylococcal Infections
Primary: Number of Participants With Adverse Drug Reaction Not Expected From the Japanese Package Insert. — 1; 1; 1; 1 participants
Gastrointestinal Stromal Tumors
Primary: Number of Participants With Treatment-Related Adverse Events — 450 Participants
Acute Pain · Dysmenorrhea
Primary: Percentage of Patients With an Incidence of Adverse Event (AE) Associated to Potential Liver Damage During the Clinical Evaluation of Patients — 0.0 Percentage of Patients
Opioid Abuse
Primary: Subjective Ratings of "Good" Drug Effect — 37; 35; 35 units on a scale
Transthyretin Familial Amyloid Polyneuropathy
Primary: Percentage of Participants With ADRs in This Study — 58; 12 Participants
Healthy
Primary: NK-104 AUC — 208.92 ng * h/mL
Drug-Drug Interaction · Healthy Volunteers
Primary: Lovastatin AUC in the Presence of Fluoxetine — 170; 180 nmol*hr/L — p=>0.05
HIV Infection
Primary: Number of Participants With the Frequency of Treatment Related Adverse Events. — 73; 10 participants